Patient-derived xenografts (PDX) can adequately reflect clinical drug efficacy. However, the
methods for evaluating drug efficacy are not fully established. We selected five non–small …

Availability of lung cancer models that closely mimic human tumors remains a significant
gap in cancer research, as tumor cell lines and mouse models may not recapitulate the …

Patient-derived xenograft (PDX) models are an effective preclinical in vivo platform for
testing the efficacy of novel drugs and drug combinations for cancer therapeutics. Here we …

Background Treatment of human lung squamous cell carcinoma (LUSC) using current
targeted therapies is limited because of their diverse somatic mutations without any specific …

Objective: Patient-derived xenograft (PDX) models have shown great promise in preclinical
and translational applications, but their consistency with primary tumors in phenotypic …

Background Preclinical models that can better predict therapeutic activity in clinical trials are
needed in this era of personalized cancer treatment. Herein, we established genomically …

The search for preclinical models that accurately reflect the complexity and heterogeneity of
human cancer genomics, and moreover are predictive of sensitivity and resistance patterns …

Patient-derived xenograft (PDX) models for cancer research have recently attracted
considerable attention in both the academy and industry (Hidalgo et al., 2014; Wilding and …

Purpose In the pursuit of creating personalized and more effective treatment strategies for
lung cancer patients, Patient-Derived Xenografts (PDXs) have been introduced as …

Patient‐derived xenograft (PDX) models are a useful tool in cancer biology research.
However, the number of lung cancer PDX is limited. In the present study, we successfully …